Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin stockholders elect 10 directors, approve 7.65 million share increase to equity plan

Neutral Impact 2 of 5 shareholder Written later

At its June 2, 2026 annual meeting, BioMarin stockholders elected all ten director nominees, ratified KPMG LLP as the auditor for fiscal 2026, and gave a non-binding approval to executive pay. They also approved a 7,650,000-share increase to the 2017 Equity Incentive Plan, which took effect immediately and adds shares available for equity awards.

Key points

  • Ten directors elected; Ian T. Clark drew the most against votes at 19,160,530.
  • Equity plan amendment approved with 158,561,867 for and 5,480,380 against.
  • Advisory say-on-pay vote approved with 142,742,800 for and 21,287,767 against.
  • KPMG LLP ratified for the fiscal year ending December 31, 2026, with 170,867,335 for.

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECJun 4, 2026, 4:24 PM ET
Accession number0001628280-26-040812

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.